Comparison of characteristics of patients with lung cancer in U.K. primary care databases: Clinical Practice Research Datalink A urum and GOLD
Pharmacoepidemiology and Drug Safety · 2023
DOI: 10.1002/pds.5637 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pharmacoepidemiology and Drug Safety, 2023. Verfasst von J L Gulikers und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Pharmacy & Toxicology, Maastricht University Medical Centre+, Maastricht, The Netherlands. Hauptthemen laut MEDLINE: Electronic Health Records, Lung Neoplasms. Die Arbeit nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Introduction
In recent years, the number of general practices contributing to the Clinical Practice Research Datalink (CPRD) database GOLD is decreasing. Therefore, for research questions addressing for instance novel treatments requiring up‐to‐date data, sample size will become an important consideration in study feasibility. In recent years, CPRD Aurum, containing information of practices that use EMIS software, has become an additional data source that is being used for CPRD studies. In order to establish whether Aurum is suited to act as data source for future studies in the field of lung cancer research, we aimed to compare characteristics between patients with lung cancer in Aurum and GOLD.
Methods
A retrospective study was performed comparing characteristics and overall survival (OS) of patients with lung cancer in Aurum and GOLD. To further evaluate similarity, hypothetical eligibility of these patients in Aurum and GOLD was compared for 11 randomized clinical trials (RCTs).
Results
Baseline characteristics registered in Aurum and GOLD were largely similar, with some clinically irrelevant differences for previous malignancies, deviant laboratory values and drug use. Median OS was 9.8 and 9.0 months for patients in Aurum and GOLD, respectively. Potential RCT eligibility varied between 49.4% and 79.5% and 49.1% and 78.1% for patients in Aurum and GOLD, respectively. Mortality rates and the comparison of the obtained HRs per hypothetical eligibility cohort per RCT were similar in Aurum and GOLD.
Conclusion
This study showed that data of patients with lung cancer in Aurum and GOLD are largely comparable, suggesting that Aurum is suitable for future epidemiological lung cancer research.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Clinical Pharmacy & Toxicology, Maastricht University Medical Centre+, Maastricht, The Netherlands.
- CARIM School for Cardiovascular Disease, Maastricht University, Maastricht, The Netherlands.
- Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, The Netherlands.
- NUTRIM, Maastricht University Medical Centre+, Maastricht, The Netherlands.
- Division Medical Oncology, GROW, Maastricht University Medical Centre+, Maastricht, The Netherlands.
- Department of Pulmonary Diseases, GROW, Maastricht University Medical Centre+, Maastricht, The Netherlands.
ORCID-Profile: J L Gulikers
Zitieren
APA
Gulikers, J. L., van Veelen, A. J., Driessen, J. H. M., Souverein, P. C., Tjan-Heijnen, V. C. G., Hendriks, L. E. L., van Geel, R. M. J. M., & Croes, S. (2023). Comparison of characteristics of patients with lung cancer in U.K. primary care databases: Clinical Practice Research Datalink A urum and GOLD. Pharmacoepidemiology and Drug Safety. https://doi.org/10.1002/pds.5637
Vancouver
Gulikers JL, van Veelen AJ, Driessen JHM, Souverein PC, Tjan-Heijnen VCG, Hendriks LEL, et al. Comparison of characteristics of patients with lung cancer in U.K. primary care databases: Clinical Practice Research Datalink A urum and GOLD. Pharmacoepidemiology and Drug Safety. 2023. doi:10.1002/pds.5637
BibTeX
@article{Gulikers2023,
author = {Gulikers, J L and van Veelen, A J and Driessen, J H M and Souverein, P C and Tjan-Heijnen, V C G and Hendriks, L E L and van Geel, R M J M and Croes, S},
title = {Comparison of characteristics of patients with lung cancer in U.K. primary care databases: Clinical Practice Research Datalink A urum and GOLD},
journal = {Pharmacoepidemiology and Drug Safety},
year = {2023},
doi = {10.1002/pds.5637}
}
EUVIMED